1. Home
  2. NEXT vs ATAI Comparison

NEXT vs ATAI Comparison

Compare NEXT & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NextDecade Corporation

NEXT

NextDecade Corporation

HOLD

Current Price

$8.31

Market Cap

1.5B

Sector

Energy

ML Signal

HOLD

ATAI

ATAI Life Sciences N.V.

HOLD

Current Price

$3.83

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEXT
ATAI
Founded
2010
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
NEXT
ATAI
Price
$8.31
$3.83
Analyst Decision
Hold
Strong Buy
Analyst Count
2
8
Target Price
$7.50
$15.13
AVG Volume (30 Days)
6.3M
4.0M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$308,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.75
$1.15
52 Week High
$12.12
$6.73

Technical Indicators

Market Signals
Indicator
NEXT
ATAI
Relative Strength Index (RSI) 71.76 55.70
Support Level $8.09 $3.60
Resistance Level $9.08 $4.30
Average True Range (ATR) 0.68 0.20
MACD 0.07 0.04
Stochastic Oscillator 90.89 79.43

Price Performance

Historical Comparison
NEXT
ATAI

About NEXT NextDecade Corporation

NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas, the sale of LNG, and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions, advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.

About ATAI ATAI Life Sciences N.V.

AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

Share on Social Networks: